Acumen Hypotension Prediction Index (HPI) Feature Software vs AHI System
AI Verdict
When considering AI tools for predicting hemodynamic instability, physicians can choose between Edwards Lifesciences’ Acumen HPI Feature Software and Fifth Eye’s AHI System. Acumen HPI excels at predicting hypotensive events up to 15 minutes in advance, utilizing machine learning on blood pressure waveforms to provide a quantitative HPI score and insights into preload, afterload, and contractility. It is integrated into the Edwards Lifesciences HemoSphere platform and is best suited for settings where invasive or non-invasive blood pressure monitoring is already a standard, such as in anesthesiology or critical care, allowing for proactive management of impending hypotension.
In contrast, Fifth Eye’s AHI System offers real-time predictive analytics for hemodynamic instability, detecting patient deterioration hours before changes in vital signs by analyzing continuous Lead II ECG signals. This software-only device integrates with existing hospital IT infrastructure and patient monitoring platforms, making it a flexible option for broader deployment across critical care, emergency medicine, and hospital medicine. The key practical difference lies in their data input and prediction window: Acumen HPI focuses on blood pressure dynamics for short-term hypotension prediction, while AHI leverages ECG signals for earlier, broader detection of hemodynamic instability.
Physicians prioritizing precise, short-term prediction and detailed hemodynamic parameter insights, particularly in perioperative or intensive care settings with existing Edwards Lifes Lifesciences monitoring, would find Acumen HPI more aligned with their needs. Conversely, those seeking an earlier, more generalized warning of hemodynamic instability across a wider range of hospital settings, utilizing readily available ECG data and a software-only deployment, would likely prefer Fifth Eye’s AHI System for its ability to provide hours of lead time before vital sign changes.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist